Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children.

ABSTRACT:

Importance

Contemporary North American trials for children with Hodgkin lymphoma (HL) have decreased radiation therapy (RT) use and increased pharmacologic cardioprotection but also increased the cumulative doxorubicin dose, making overall treatment consequences for late cardiac toxic effects uncertain.

Objective

To estimate the risk of cardiac toxic effects associated with treatments used in modern pediatric HL clinical trials.

Design, setting, and participants

For this cohort study, Fine and Gray models were fitted using survivors in the Childhood Cancer Survivor Study who were diagnosed with HL between January 1, 1970, and December 31, 1999, and were followed for a median of 23.5 (range, 5.0-46.3) years. These models were applied to the exposures in the study popul

SUBMITTER: Lo AC 

PROVIDER: S-EPMC10799264 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature